MYCN Reprograms Neuroblastoma Metabolism
National Technical Information Service; 2020.
Non-conventional
in English
| National Technical Information Service | ID: grc-753463
ABSTRACT
Despite current aggressive regimens, the majority of patients with MYCN amplification die due to drug-resistant disease, and further intensification ofchemotherapy will not significantly improve this outcome. We propose an entirely novel strategy to oppose MYCN oncogenic function in NB by blockingthe metabolic reprogramming driven by MYCN. Based on our data and the recent literature, our guiding hypotheses are that a) lipid metabolism is requiredfor NB tumorigenesis, and b) targeting MYCN-driven lipogenesis will effectively block NB tumor growth. We have demonstrated that lipid metabolism is aselective metabolic dependency of MYCN-driven tumors. MYCN drives both fatty acid (FA) synthesis and FA uptake to maintain NB cell survival. TargetingFA uptake effectively blocks NB in vivo tumor growth.
CELL PHYSIOLOGICAL PROCESSES; HEALTH SERVICES; MEDICAL PERSONNEL; THERAPY; LIPID METABOLISM; BIOMEDICAL RESEARCH; FATTY ACIDS; DISEASES AND DISORDERS; COMBINATION THERAPY; COVID-19; INHIBITION; INHIBITORS; METABOLISM; NEOPLASMS; BIOLOGICAL STAINING AND LABELING; CELL LINE; CELLS; LAW; LIPIDS; MARYLAND
Full text:
Available
Collection:
Databases of international organizations
Database:
National Technical Information Service
Type of study:
Prognostic study
Language:
English
Year:
2020
Document Type:
Non-conventional
Similar
MEDLINE
...
LILACS
LIS